You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.
On a conference call to discuss the company's third quarter financial results, executives said they increased molecular test production by 50 percent during the quarter.
The agency has provided new guidance for tests that can be used outside of a lab setting, as well as updated its guidance on a number of other topics.
PharmaCyte licensed the RT-PCR and enhanced fluorescence RT-PCR tests from Hong Kong-based Hai Kang Life.
Strong demand for the firm's COVID-19 molecular tests for the Panther and Panther Fusion platforms offset revenue declines in other areas of the business.
Both of the RT-PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in a variety of swab samples and other specimens.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
New offerings from the oncology testing company include Inivita's InvisionFirst-Lung test and the NeoLab solid tumor test.
The tube, cap, and multitube consumables enable SARS-CoV-2 tests on its automated Panther and Panther Fusion sample-to-answer molecular diagnostic systems.
By screening swine samples at thousands of European farms, researchers saw reassorted versions of the 2009 H1N1 swine flu virus that may be able to dodge human immunity.
The FluoroType SARS-CoV-2 plus real-time PCR test can distinguish SARS-CoV-2 from other coronaviruses that can cause the common cold.
Both PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid and ORF1ab genes, while Helix's assay also detects the virus' spike protein gene.
The FDA reissued the EUA after analyzing LabCorp data that showed the test could detect SARS-CoV-2 in a general asymptomatic population.
Cities and start-ups are pushing to incorporate SARS-CoV-2 wastewater monitoring into pandemic responses even as basic science researchers scramble to hammer out methods.
The firm currently has seven available products, including high- and low-throughput molecular tests and an antibody test for the virus.
The firm's COVID-19 molecular offerings almost made up for the decline in routine testing resulting from the pandemic.
The test is designed to detect the SARS-CoV-2 Orf1ab gene in upper respiratory specimens and sputum, according to the California-based company.
Researchers at the University of Washington found that home-collected nasal swabs were about 80 percent sensitive compared to nasopharyngeal swabs collected by clinicians.
The firm saw revenues grow 10 percent in Q2, in part driven by PCR-based COVID-19 testing, as it increased production capacity to 10 million tests per week.
The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.